John Theurer Cancer Center @HackensackUMC is among the nation's top cancer hospitals with 14 specialized divisions providing the most advanced care possible.
Carfilzomib, iberdomide, and dexamethasone (KID) therapy before autologous transplant showed a 98% response rate in multiple #myeloma, with 31% achieving complete or stringent complete response.
📰 Read more from a study led by @BiranNoa of @HMHNewJersey@JTCancerCenter.
➡️ buff.ly/qJsSWMn
📍 We’re onsite today at @JTCancerCenter@HMHNewJersey!
From breast to colorectal and gynecologic cancers, we’re sitting down with leading experts to discuss the latest in cancer care. Stay tuned for new interviews coming soon! 🎥
#Oncology#CancerCare#CancerResearch
👀 Robotic surgery, transvesical approaches, and the single-port era, were all topics covered by @RoboticsUrology of @JTCancerCenter in his commentary on paradigm shifts in minimally invasive surgeries.
Full details here 🤖: hubs.li/Q040d3MB0#pcsm#oncology
🩺 The Three Pillars of #PancreasCancer Treatment
Dr. Benjamin Jon Golas, of @JTCancerCenter, breaks down how surgery, chemo, and radiation form the foundation of curative-intent therapy for pancreas cancer.
Learn more and wathc the whole video here! hubs.li/Q03_0mQK0
CONGRESS | #ASH25 | PRESENTATION
Lori Leslie shares 3-year results from the phase Ib/II EPCORE NHL-2 trial, of 1L epcoritamab with rituximab + lenalidomide (Arm 6; n = 41) and epcoritamab maintenance monotherapy following SOC (Arm 7; n = 19), in patients with FL.
The ORR with epcoritamab + rituximab + lenalidomide in Arm 6 was 95% and the CR rate was 88%. In Arm 7, 100% of patients with PR from last line of therapy (n = 8) achieved CR after a median of 2.8 months (range, 2.5–5.7). No new safety signals were observed in either arm; the majority of TEAEs were infectious in nature.
Data indicate favorable safety and efficacy of epcoritamab, in combination with rituximab in 1L and as maintenance monotherapy, in FL.
Follow our live feed for more updates: loom.ly/POS6cqk
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma#lymsm#MedEd#MedicalCongress@LoriLeslieMD@HMHNewJersey
📺 Watch “Your New Jersey” Saturdays at 6 AM and Sundays at 8 AM on MeTV WJLP New Jersey/New York!
This weekend:
1️⃣ Lindsay Colameo Peragallo, Founder of Beauty Holiday and & Lauren Encarnacion, Project Coordinator at @HMHNewJersey John Theurer Cancer Center, sharing how their collaboration brings self-care packages to patients undergoing treatment💄
2️⃣ Lauren D’Amelio, Founder of D’Amelio Cosmetics & Nicolette Dalessandro, Celebrity Makeup Artist discuss empowering artists, running high-profile events, and giving back through their work✨
For more information, visit UpdateNewJersey.com#TV#Television#YourNewJersey#UpdateNewJersey#MeTV#WJLP#NewJersey#NJ#Watch#Local#Community#GivingBack#BeautyIndustry#SelfCare#Inspiration#LocalLife
Eating well during cancer treatment can be challenging.
In this interview with CURE, registered dietitian Kanisha Parikh from John Theurer Cancer Center shares practical tips for maintaining nutrition when eating becomes difficult.
curetoday.com/view/eating-ti…@HMHNewJersey
🥗 Safe food matters, especially for immunocompromised patients with #Cancer!
Dietitian Heather Ann Yonker, of @JTCancerCenter, shares step-by-step tips for handling, cooking, and storing poultry safely at home.
Learn more from CURE! 👇 hubs.li/Q03LK4Nr0